Similar articles

• Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.

  Gavin LA, Barth J, Arnold D, Shaw R. Gavin LA, et al. Endocr Pract. 2000 Jul-Aug;6(4):305-10. doi: 10.4158/EP.6.4.305. Endocr Pract. 2000. PMID: 11242607
• Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.

  Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, Park JY. Kang YM, et al. Diabetes Metab J. 2019 Aug;43(4):432-446. doi: 10.4093/dmj.2018.0092. Epub 2019 Jun 19. Diabetes Metab J. 2019. PMID: 31237133 Free PMC article. Clinical Trial.
• Comparison of Metformin-sulfonylurea and Metformin-acarbose Combination Therapies on Glycemic Outcomes: A Retrospective Cohort Study.

  Wafa W, Septini R, Sauriasari R. Wafa W, et al. Curr Diabetes Rev. 2022;18(7):e031121197656. doi: 10.2174/1573399818666211103161917. Curr Diabetes Rev. 2022. PMID: 34732117
• [Tough glucose reduction necessary in newly diagnosed diabetes].

  Rydén M. Rydén M. Lakartidningen. 2010 Nov 10-16;107(45):2810-4. Lakartidningen. 2010. PMID: 21179867 Review. Swedish. No abstract available.
• Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.

  Scheen AJ. Scheen AJ. Diabetes Metab. 2020 Jun;46(3):186-196. doi: 10.1016/j.diabet.2020.01.002. Epub 2020 Jan 30. Diabetes Metab. 2020. PMID: 32007623